| 1 |
29313279 | A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. | 2018 Oct |
2 |
| 2 |
26508094 | A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. | 2016 Jan |
1 |
| 3 |
23032073 | A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD. | 2013 Feb |
2 |
| 4 |
21748252 | Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. | 2012 Feb |
2 |
| 5 |
22393246 | ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines. | 2012 Jun |
1 |
| 6 |
22464442 | Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells. | 2012 Mar 30 |
1 |
| 7 |
22764103 | Granzyme B triggers a prolonged pressure to die in Bcl-2 overexpressing cells, defining a window of opportunity for effective treatment with ABT-737. | 2012 Jul 5 |
2 |
| 8 |
23190604 | ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells. | 2012 Nov 29 |
5 |
| 9 |
21933888 | Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. | 2011 Nov 15 |
1 |
| 10 |
19632048 | A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain. | 2009 Dec |
3 |
| 11 |
17943175 | Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. | 2008 Jan |
1 |
| 12 |
16143263 | Potent farnesyltransferase inhibitor ABT-100 abrogates acute allograft rejection. | 2005 Sep |
3 |